MY159560A - Quinoline derivatives as antibacterial agents - Google Patents
Quinoline derivatives as antibacterial agentsInfo
- Publication number
- MY159560A MY159560A MYPI20063727A MYPI20063727A MY159560A MY 159560 A MY159560 A MY 159560A MY PI20063727 A MYPI20063727 A MY PI20063727A MY PI20063727 A MYPI20063727 A MY PI20063727A MY 159560 A MY159560 A MY 159560A
- Authority
- MY
- Malaysia
- Prior art keywords
- alkyl
- het
- hydrogen
- alkylthio
- hydroxy
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- -1 CYANO, HYDROXY Chemical class 0.000 abstract 4
- 150000003254 radicals Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
USE OF A COMPOUND FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A BACTERIAL INFECTION PROVIDED THAT THE BACTERIAL INFECTION IS OTHER THAN A MYCOBACTERIAL INFECTION, SAID COMPOUND BEING A COMPOUND OF FORMULA (I) A PHARMACEUTICALLY ACCEPTABLE ACID OR BASE ADDITION SALT, A QUATERNARY AMINE, A STEREOCHEMICALLY ISOMERIC FORM, A TAUTOMERIC FORM OR A N-OXIDE FORM THEREOF, WHEREIN R1 IS HYDROGEN. HALO, HALOALKYL, CYANO, HYDROXY, AR, HET, ALKYL, ALKYLOXY, ALKYLTHIO, ALKYLOXYALKYL, ALKYLTHIOALKYL, AR-ALKYL OR DI(AR)ALKYL; P IS 1 TO 3; S IS 0 TO 4; R2 IS HYDROGEN; HALO; ALKYL; HYDROXY; MERCAPTO; OPTIONALLY SUBSTITUTED ALKYLOXY; ALKYLOXYALKYLOXY; ALKYLTHIO; MONO OR DI(ALKYL)AMINO WHEREIN ALKYL MAY OPTIONALLY BE SUBSTITUTED; AR; HET OR A RADICAL OF FORMULA; R3 IS ALKYL, AR, AR-ALKYL, HET OR HET-ALKYL; Q IS 0 TO 4 ; R4 AND R5 EACH INDEPENDENTLY ARE HYDROGEN, ALKYL OR BENZYL; OR R4 AND R5 MAY BE TAKEN TOGETHER INCLUDING THE N TO WHICH THEY ARE ATTACHED ; R6 IS HYDROGEN, HALO, HALOALKYL, HYDROXY, AR, ALKYL, ALKYLOXY, ALKYLTHIO, ALKYLOXYALKYL, ALKYLTHIOALKYL, AR-ALKYL OR DI(AR)ALKYL ; OR TWO VICINAL R6 RADICALS MAY BE TAKEN TOGETHER TO FORM TOGETHER WITH THE PHENYL RING TO WHICH THEY ARE ATTACHED A NAPHTHYL; R IS 1 TO 5 ; R7 IS HYDROGEN, ALKYL, AR OR HET ; R8 IS HYDROGEN, ALKYL, HYDROXYL, AMINOCARBONYL, MONO-OR DI(ALKYL)AMINOCARBONYL, AR, HET, ALKYL SUBSTITUTED WITH ONE OR TWO HET, ALKYL SUBSTITUTED WITH ONE OR TWO AR, HET-C(=O)- OR AR-C(=O)-; PROVIDED THAT WHEN THE R3 BEARING RADICAL IS PLACED IN POSITION 3 OF THE QUINOLINE MOIETY; R7 IS PLACED IN POSITION 4 AND R2 IS PLACED IN POSITION 2 AND REPRESENTS HYDROGEN, HYDROXY, MERCAPTO, ALKYLOXY, ALKYLOXYALKYLOXY, ALKYLTHIO, MONO OR DI(ALKYL)AMINO OR A RADICAL OF FORMULA THEN S IS 1 TO 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107164 | 2005-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY159560A true MY159560A (en) | 2017-01-13 |
Family
ID=35744723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20063727A MY159560A (en) | 2005-08-03 | 2006-08-01 | Quinoline derivatives as antibacterial agents |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8802671B2 (en) |
| EP (1) | EP1912648B1 (en) |
| JP (1) | JP5302680B2 (en) |
| KR (1) | KR101413997B1 (en) |
| CN (2) | CN101277696A (en) |
| AP (1) | AP2654A (en) |
| AR (1) | AR054890A1 (en) |
| AU (1) | AU2006274880B2 (en) |
| BR (1) | BRPI0614493B8 (en) |
| CA (1) | CA2615903C (en) |
| CY (1) | CY1114318T1 (en) |
| DK (1) | DK1912648T3 (en) |
| EA (1) | EA014833B1 (en) |
| ES (1) | ES2414956T3 (en) |
| HR (1) | HRP20130540T1 (en) |
| IL (1) | IL189142A0 (en) |
| JO (1) | JO2855B1 (en) |
| ME (1) | ME01616B (en) |
| MX (1) | MX2008001603A (en) |
| MY (1) | MY159560A (en) |
| NO (1) | NO341242B1 (en) |
| NZ (1) | NZ565947A (en) |
| PL (1) | PL1912648T3 (en) |
| PT (1) | PT1912648E (en) |
| RS (1) | RS52808B (en) |
| SI (1) | SI1912648T1 (en) |
| TW (1) | TWI422374B (en) |
| UA (1) | UA95915C2 (en) |
| WO (1) | WO2007014941A2 (en) |
| ZA (1) | ZA200801110B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004186452A (en) | 2002-12-04 | 2004-07-02 | Renesas Technology Corp | Nonvolatile semiconductor memory device and manufacturing method thereof |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Antibacterial Quinoline Derivatives |
| JO3271B1 (en) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | Antibacterial Quinoline Derivatives |
| PL2841425T3 (en) | 2012-04-27 | 2016-10-31 | Antibacterial quinoline derivatives | |
| US9617244B2 (en) | 2012-04-27 | 2017-04-11 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| ES2628365T3 (en) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Phenyl-linked quinolinyl modulators of ROR-GAMA-T |
| KR20150070347A (en) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Methylene linked quinolinyl modulators of ror-gamma-t |
| HK1213250A1 (en) | 2012-10-16 | 2016-06-30 | Janssen Pharmaceutica, N.V. | Heteroaryl linked quinolinyl modulators of roryt |
| AU2014334619A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| KR20160068956A (en) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | QUINOLINYL MODULATORS OF RORyT |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| CN109111397B (en) * | 2018-08-28 | 2021-12-10 | 广东工业大学 | Quinoline aromatic ethylene derivative and preparation method and application thereof |
| CN109111396B (en) * | 2018-08-28 | 2021-09-03 | 广东工业大学 | Quinoline aromatic vinyl derivative and preparation method and application thereof |
| CN112110907B (en) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | A compound containing 1,4-dioxane dimerized bisthiophene structure and its preparation method and application |
| CN112079825B (en) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | Compound containing 1,3-dioxolane dimerized bisthiophene structure and preparation method and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB807750A (en) | 1956-06-15 | 1959-01-21 | Rhone Poulenc Sa | Improvements in or relating to piperazine derivatives |
| GB9317491D0 (en) * | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
| WO1998018326A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| AR040336A1 (en) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND |
| DK2301544T3 (en) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinoline derivatives as intermediates for mycobacterial inhibitors |
| PL360102A3 (en) | 2003-05-13 | 2004-11-15 | "ENERGOMAR-NORD" Sp.z o.o. | Method for manufacturing highly reactive calcium sorbing agents and facility designed for manufacturing highly reactive calcium sorbing agents |
| ATE444068T1 (en) | 2004-01-23 | 2009-10-15 | Janssen Pharmaceutica Nv | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS |
| NZ547277A (en) | 2004-01-23 | 2009-08-28 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors |
| EA011572B9 (en) * | 2004-01-29 | 2018-01-31 | Янссен Фармацевтика Н.В. | Quinoline derivatives for use as mycobacterial inhibitors |
| EE05697B1 (en) | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| US20070018948A1 (en) | 2005-07-22 | 2007-01-25 | Elaine Chen | Apparatus for stabilizing an electronic device during data input and device control |
-
2006
- 2006-07-18 JO JO2006232A patent/JO2855B1/en active
- 2006-07-31 HR HRP20130540TT patent/HRP20130540T1/en unknown
- 2006-07-31 AU AU2006274880A patent/AU2006274880B2/en not_active Ceased
- 2006-07-31 DK DK06778083.3T patent/DK1912648T3/en active
- 2006-07-31 BR BRPI0614493A patent/BRPI0614493B8/en not_active IP Right Cessation
- 2006-07-31 NZ NZ565947A patent/NZ565947A/en not_active IP Right Cessation
- 2006-07-31 EA EA200800508A patent/EA014833B1/en unknown
- 2006-07-31 SI SI200631602T patent/SI1912648T1/en unknown
- 2006-07-31 US US11/997,173 patent/US8802671B2/en active Active
- 2006-07-31 PT PT67780833T patent/PT1912648E/en unknown
- 2006-07-31 EP EP06778083.3A patent/EP1912648B1/en active Active
- 2006-07-31 MX MX2008001603A patent/MX2008001603A/en active IP Right Grant
- 2006-07-31 WO PCT/EP2006/064858 patent/WO2007014941A2/en not_active Ceased
- 2006-07-31 CN CNA2006800367512A patent/CN101277696A/en active Granted
- 2006-07-31 JP JP2008524509A patent/JP5302680B2/en not_active Expired - Fee Related
- 2006-07-31 AP AP2008004316A patent/AP2654A/en active
- 2006-07-31 RS RS20130254A patent/RS52808B/en unknown
- 2006-07-31 ME MEP-2013-65A patent/ME01616B/en unknown
- 2006-07-31 PL PL06778083T patent/PL1912648T3/en unknown
- 2006-07-31 ES ES06778083T patent/ES2414956T3/en active Active
- 2006-07-31 CA CA2615903A patent/CA2615903C/en active Active
- 2006-07-31 UA UAA200801432A patent/UA95915C2/en unknown
- 2006-07-31 KR KR1020087005071A patent/KR101413997B1/en not_active Expired - Fee Related
- 2006-07-31 CN CN200680036751.2D patent/CN101277696B8/en not_active Expired - Fee Related
- 2006-08-01 MY MYPI20063727A patent/MY159560A/en unknown
- 2006-08-02 AR ARP060103372A patent/AR054890A1/en unknown
- 2006-08-02 TW TW095128224A patent/TWI422374B/en not_active IP Right Cessation
-
2008
- 2008-01-31 IL IL189142A patent/IL189142A0/en active IP Right Grant
- 2008-02-01 ZA ZA2008/01110A patent/ZA200801110B/en unknown
- 2008-02-27 NO NO20081026A patent/NO341242B1/en not_active IP Right Cessation
-
2013
- 2013-07-09 CY CY20131100578T patent/CY1114318T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY159560A (en) | Quinoline derivatives as antibacterial agents | |
| TW200744594A (en) | Quinoline derivatives as antibacterial agents | |
| MY145845A (en) | Treatment of latent tuberculosis | |
| NO20080499L (en) | Quinoline derivatives as antibacterial agents | |
| NO20081068L (en) | Quinoline derivatives as antibacterial agents | |
| NO20080501L (en) | Quinoline derivatives as antibacterial agents | |
| TW200738237A (en) | Quinoline derivatives as antibacterial agents | |
| JO2695B1 (en) | Treatment of latent tuberculosis | |
| TH87171B (en) | Quinoline derivatives are antibacterial agents. |